Sigma-Aldrich Enters Distribution Agreement with MitoProd
News Mar 20, 2009
Under the terms of the agreement, MitoProd will produce custom long RNA oligonucleotides for Sigma-Aldrich customers. The partnership further expands Sigma-Aldrich's comprehensive custom oligonucleotide service portfolio.
RNA molecules offer significant promise for a variety of applications in therapeutics and pharmaceutical development and production. MitoProd has developed a proprietary technology that enables the in vivo synthesis of ribonucleic acids. Based on baker yeast fermentation, MitoProd's technology enables the production of large homogeneous batches of ribonucleic acids without limitation on length or quantity.
"Sigma-Aldrich's established distribution network will greatly expand the market for our custom RNA products and services," said Guillaume Plane, CEO of MitoProd SA. "We are proud to collaborate with such a well-known life science company."
"This partnership further augments Sigma-Aldrich's portfolio of custom life science tools," said Khalil Arar, Business Development Director of Sigma-Aldrich Custom Products. "Harnessing MitoProd's technology, we can now offer customized long RNA synthesis capabilities to our life science customers worldwide."
Sigma-Aldrich offers a comprehensive collection of customized oligonucleotide services, from DNA oligos and probes to RNA and siRNA oligos and peptide synthesis.
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
RNA Molecules Lives Are 10 Times Shorter Than Previously ThoughtNews
A research group at the Biozentrum of the University of Basel has developed a new method to measure the half-life of RNA molecules.READ MORE
Changing microRNA's Presence in Glioblastoma Cells Could Change the Tumor's SubtypeNews
BWH researchers examined a specific microRNA, miR-128, to help identify glioblastoma subtypes and to determine if altering the microRNA's presence in glioblastoma cells could change the tumor's subtype.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018